Memantine LEK

Country: Европска Унија

Језик: Шпански

Извор: EMA (European Medicines Agency)

Активни састојак:

clorhidrato de memantina

Доступно од:

Pharmathen S.A.

АТЦ код:

N06DX01

INN (Међународно име):

memantine

Терапеутска група:

Psychoanaleptics, , Otras drogas anti-demencia

Терапеутска област:

Enfermedad de Alzheimer

Терапеутске индикације:

Tratamiento de pacientes con enfermedad de Alzheimer de moderada a grave.

Резиме производа:

Revision: 5

Статус ауторизације:

Autorizado

Датум одобрења:

2013-04-21

Информативни летак

Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on [phone].
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call [phone] outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]

Карактеристике производа

Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on [phone].
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call [phone] outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]